Navigation Links
Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine™ Data
Date:10/12/2010

SOUTH SAN FRANCISCO, Calif., Oct. 12 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (OTC Bulletin Board: TTNP) today announced that data from its previously completed and announced Phase 3 randomized, placebo-controlled clinical trial of Probuphine were published in the Journal of the American Medical Association (JAMA).  The article highlights data from the 163-patient trial, which showed that patients receiving Titan's Probuphine implant had significantly less illicit opioid use, experienced fewer symptoms of withdrawal and craving, stayed in treatment longer and had greater overall improvement when compared to placebo patients over the course of the 24-week study.

Probuphine is an innovative, subcutaneous implant formulation designed using Titan's proprietary ProNeura™ technology to deliver a steady, round-the-clock low dose of the marketed drug buprenorphine over six months following a single treatment.

"The introduction of buprenorphine into clinical practice is arguably the most significant improvement in the treatment of opioid addiction in the last decade; however, physicians excited with the clinical success of buprenorphine are also rightfully concerned about medication adherence and diversion - and potential for abuse - of the sublingual formulations of buprenorphine," said Walter Ling, M.D., Professor of Psychiatry and Director, Integrated Substance Abuse Programs at the David Geffen School of Medicine at UCLA and the paper's lead author.  "Probuphine does away with these concerns by eliminating the need for take home doses. Additionally, by providing a sustained blood level of active medication, Probuphine helps diminish the daily fluctuation of the medication effects—and potentially side effects-- and reduces the total exposure of buprenorphine over time."  

The publication, "Buprenorphine Implants for Opioid Depende
'/>"/>

SOURCE Titan Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ascension Orthopedics Announces First Implantations of TITAN™ Modular Shoulder
2. Ascension Orthopedics Receives FDA Approval for TITAN™ Modular Total Shoulder System
3. Cardiac Dimensions® Announces Presentation of 12-Month Follow-up Data of TITAN™ Trial at European Society of Cardiology Meeting
4. Titan Pharmaceuticals Announces Second Quarter 2010 Financial Results
5. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
6. Reportlinker Adds Sales Force Effectiveness in Pharmaceuticals - Cost Pressures Increase Pharmaceutical Companies Adoption of New Sales Models and Technologies
7. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
8. Jazz Pharmaceuticals Receives FDA Complete Response Letter Regarding JZP-6 for Treatment of Fibromyalgia
9. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
10. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
11. Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 Adaptive ... Next Generation Sequencing to profile the adaptive immune ... Scientific Advisory Board to provide strategic and clinical ... suite of assays in the diagnosis and monitoring ... focus of the SAB will be to support ...
(Date:9/29/2014)... BOSTON , Sept. 29, 2014  Arisaph ... on discovery and development of novel therapies for ... has been awarded a phase II Small Business ... I grant, both from the National Cancer Institute ... II award of $1,066,916 supports research and development ...
(Date:9/29/2014)... TEL-AVIV, Israel , Sept. 29, 2014 /PRNewswire/ ... ) ("Galmed"), a clinical-stage biopharmaceutical company focused on ... medication for the treatment of liver diseases and ... EndoPAT™ devices and accessories from Itamar Medical Ltd. ... company whose technology has been cleared by the ...
Breaking Medicine Technology:Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 3Arisaph Pharmaceuticals Awarded Supplemental Phase I And Phase II STTR Grants To Develop Oncology Drug Candidates 2Arisaph Pharmaceuticals Awarded Supplemental Phase I And Phase II STTR Grants To Develop Oncology Drug Candidates 3Arisaph Pharmaceuticals Awarded Supplemental Phase I And Phase II STTR Grants To Develop Oncology Drug Candidates 4Galmed Pharmaceuticals and Itamar Medical to Collaborate on Assessing Aramchol's Effect on Endothelial Function 2Galmed Pharmaceuticals and Itamar Medical to Collaborate on Assessing Aramchol's Effect on Endothelial Function 3
... Hospira, Inc. (NYSE: HSP ... announced positive results from a Phase I U.S. clinical ... renal (kidney) dysfunction who have anemia. Hospira,s trial met ... and distribution in the body, for Hospira,s EPO and ...
... 6, 2011 Omthera Pharmaceuticals, Inc., a privately-held emerging ... and Chief Executive Officer, will present at the Rodman ... 2011 at 2:25pm ET at the Waldorf Astoria Hotel ... Pharmaceuticals, Inc. Founded in 2008, Omthera ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
(Date:9/29/2014)... CuteBobble.com, an experienced supplier that provides ... new collection of custom bobbleheads for Christmas. ... these quality items. Moreover, all the company’s old and ... code: 10USDOFF). The promotion will last until December 15, ... new designs of custom bobbleheads . Now, our ...
(Date:9/29/2014)... (PRWEB) September 30, 2014 Shoulder pain is ... those with persistent shoulder pain generates nearly ¾ of the ... 20-33% of all adults will experience shoulder pain, and of ... has also been reported that 1 in 4 people with ... less than a year. , “This is a real problem, ...
(Date:9/29/2014)... FL (PRWEB) September 30, 2014 Only ... than $20 can improve well-being, says Sublime Beauty®.The secret ... in Skin Brushes and have introduced thousands to this ... , Heshelow was interviewed recently on the eHealth ... to learn more . , "We have just released ...
(Date:9/29/2014)... (PRWEB) September 30, 2014 Foundations Recovery ... to announce the start of its 40th national conference ... Greenwald as a featured keynote speaker at the Moments ... experts specializing in the fields of addiction and mental ... Palm Beach, Fla., September 29 – October 2, 2014, ...
(Date:9/29/2014)... Atlanta, GA (PRWEB) September 30, 2014 In ... Whiter Image Dental has recently implemented some principles from the ... company as a whole. Whiter Image CEO Brad Stevens ... the “Most eye-opening seminar [he had] ever been to.” The ... business leaders produce great results by tapping into the desire ...
Breaking Medicine News(10 mins):Health News:Customers Can Get $10 Discount Coupons For Christmas When Ordering Custom Bobbleheads At CuteBobble.com 2Health News:KORT Physical Therapist Shines a Light on Shoulder Pain and Latest Treatments 2Health News:7 Easy Steps to Skin Brushing Guide Available from Sublime Beauty®; Body Brushing Details Revealed in eHealth Radio Network Interview 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 3Health News:Whiter Image Launches Four Disciplines of Execution Initiative into Corporate Strategy 2
... 2009 The world,s top lung cancer specialists, medical ... Francisco, CA for the 13th World Conference on Lung ... Study of Lung Cancer (IASLC). Prevention and early detection ... remains one of the hardest cancers to detect in ...
... ... , ... August 2, 2009 -- United Benefit Advisors, LLC (UBA), one of the nation,s leading ... health management. , , , , ,"The majority of employers clearly recognize the potential ...
... cancer patients who have progressed on a cetuximab-containing regimen ... reported today at the annual meeting of the International ... cetuximab (Erbitux) and erlotinib (Tarceva) inhibit the epidermal growth ... once a patient progresses on one EGFR inhibitor they ...
... FRANCISCO, August 1, 2009 The world,s top lung ... week in San Francisco, CA for the 13th World ... Association for the Study of Lung Cancer (IASLC). According ... WCLC, targeted therapies, as first-line treatment, have the potential ...
... FASTRACK ... Billing & Home HealthCare Agency Billing Software System. The FASTRACK Integrated IV, HME ... single common Microsoft SQL database that allows for the connection of remote sites via ... ...
... ... by Richard K. Riegelman, is hard-wired to the Association of American Colleges ... The book is an important part of a growing movement of several ... as a critical component of good citizenship and a prerequisite for taking ...
Cached Medicine News:Health News:Diagnostic tools and innovative therapies improve patient prognosis 2Health News:Diagnostic tools and innovative therapies improve patient prognosis 3Health News:Diagnostic tools and innovative therapies improve patient prognosis 4Health News:Diagnostic tools and innovative therapies improve patient prognosis 5Health News:Diagnostic tools and innovative therapies improve patient prognosis 6Health News:Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs 2Health News:Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs 3Health News:Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapy 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 3Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 4Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 5Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 6Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 7Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 8Health News:Fastrack Release First Integrated HME Billing, Infusion Pharmacy & Home Care Agency Software in a Microsoft Environment 2Health News:New Book by Leading Authority Responds to National Initiative to Bring Undergraduate Public Health Education to All American Colleges and Universities 2Health News:New Book by Leading Authority Responds to National Initiative to Bring Undergraduate Public Health Education to All American Colleges and Universities 3
... FH system uses a ... infrastructure operating in ... communication of patient information. ... of up to 640 ...
Spacelabs offers an approach that allows your telemetry and step-down units to configure systems to meet their telemetry requirements. Our modular telemetry system data are integrated into the depart...
ISI Alumi-Hand is the safe, sterile, ready-to-use ,surgical hand immobilizer....
The Tele-Pro WEP-4200 Telemetry System is an 8-Patient Stand Alone System. Offering capabilities such as arrhythmia analysis, trends and full disclosure, the Tele-Pro is a system to help hospitals to...
Medicine Products: